Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients.

Philip Young-Ill Choi,Danny Hsu,Huyen Anh Tran,Chee Wee Tan,Anoop Enjeti,Vivien Mun Yee Chen,Eileen Merriman,Agnes S M Yong,Jock Simpson,Elizabeth Gardiner,Nicolas Cherbuin,Jennifer Curnow,Dominic Pepperell,Robert Bird

Research and practice in thrombosis and haemostasis（2023）

引用 1|浏览23

暂无评分

摘要

ITP was more frequently reported after AstraZeneca ChAdOx1 nCoV-19 than Pfizer BNT162b2 vaccination. Standard ITP treatments remain highly effective for and relapsed ITP (96%). Although thrombocytopenia can be severe after vaccination, bleeding is usually mild. Despite some sampling bias, our data do not support a change in treatment strategies for patients with ITP after vaccination.

查看译文

关键词

BNT162 vaccine,COVID-19 vaccines,ChAdOx1 nCov-19,immune thrombocytopenia,treatment outcome,vaccination

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要